lenalidomide,idecabtagene vicleucel
Bms,2Seventy Bio
['multiple myeloma', 'ide-cel']
ide-cel treatment led to frequent, deep responses in multiple myeloma patients who experienced early relapse after frontline asct, according to data presented by our dr. krona patel: #ash22 #endcancer 
MD Anderson is a global leader in cancer care, research, education and training, and prevention. Appointments available: 1-877-632-6789